These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 18580859)
1. A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction. Ritz E; Dahlöf B Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S1-2. PubMed ID: 18580859 [No Abstract] [Full Text] [Related]
2. Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection. Mancia G; Unger T; Zanchetti A J Hypertens Suppl; 2009 Jul; 27(5):S1. PubMed ID: 19587549 [No Abstract] [Full Text] [Related]
3. Cardiovascular protection: a breakthrough for high-risk patients? Ferrari R J Hypertens Suppl; 2009 Jul; 27(5):S37-40. PubMed ID: 19587554 [TBL] [Abstract][Full Text] [Related]
4. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure. Cardiovasc J Afr; 2008; 19(2):108-9; discussion 109-10. PubMed ID: 18516357 [No Abstract] [Full Text] [Related]
5. ONTARGET: How much RAS inhibition is enough? Weder AB Curr Hypertens Rep; 2009 Feb; 11(1):7-9. PubMed ID: 19146793 [No Abstract] [Full Text] [Related]
6. ARBs for cardiovascular and renal protection in high-risk patients. Aalbers J Cardiovasc J Afr; 2011; 22(4):224. PubMed ID: 21881697 [No Abstract] [Full Text] [Related]
7. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension]. MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381 [No Abstract] [Full Text] [Related]
9. [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study]. Burnier M; Waeber B; Hess O; Lüscher T Praxis (Bern 1994); 2008 May; 97(10):559-62. PubMed ID: 18595371 [No Abstract] [Full Text] [Related]
10. Where does the evidence lead us for the proper use of angiotensin II inhibitors in the management of cardiovascular disease? Guthrie RM Cardiology; 2010; 117(3):216-8. PubMed ID: 21160183 [No Abstract] [Full Text] [Related]
13. Telmisartan in high-risk cardiovascular patients. Weber MA Am J Cardiol; 2010 Jan; 105(1 Suppl):36A-43A. PubMed ID: 20102972 [TBL] [Abstract][Full Text] [Related]
14. New clinical concepts after the ONTARGET trial. Ruilope LM; Segura J; Zamorano JL Expert Rev Cardiovasc Ther; 2011 Jun; 9(6):685-9. PubMed ID: 21714599 [TBL] [Abstract][Full Text] [Related]
15. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors. Böhm M; Baumhäkel M; Mahfoud F; Werner C Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889 [TBL] [Abstract][Full Text] [Related]
17. Angiotensin receptor blockers and cardiovascular protection: are we ONTARGET? Ram CV; Deedwania PC Am J Cardiol; 2008 Nov; 102(9):1281-3. PubMed ID: 18940307 [No Abstract] [Full Text] [Related]
18. [Renin-angiotensin-aldosterone system inhibition and cardiovascular protection]. Oğuz A Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 6():4-12. PubMed ID: 20019467 [TBL] [Abstract][Full Text] [Related]
19. Renin-angiotensin system blockade and cardiovascular and renal protection. Hoogwerf BJ Am J Cardiol; 2010 Jan; 105(1 Suppl):30A-5A. PubMed ID: 20102971 [TBL] [Abstract][Full Text] [Related]